Coen Steven P. 4

What Happened

• Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks (DNA), had restricted stock units (RSUs) convert into common shares on May 21, 2026 (two conversion/settlement entries for 587 and 156 shares; total 743 shares). Following the vesting, 307 shares were sold in an open-market transaction on May 22, 2026 at $8.33 per share for total proceeds of $2,559. The filing indicates the sale was to cover tax withholding obligations related to the RSU vesting.

Key Details

• Transaction dates/prices: RSU conversion recorded 2026-05-21; open-market sale of 307 shares on 2026-05-22 at $8.33 per share (proceeds $2,559).
• Shares acquired via conversion: 587 and 156 shares (total 743) on 2026-05-21.
• Shares sold: 307 shares in open market; other converted shares were disposed/withheld as indicated in the filing to satisfy tax obligations.
• Shares owned after transaction: not specified in this Form 4.
• Notable footnotes: F1—each RSU = one share on settlement; F2—sale was a "sell to cover" to satisfy tax withholding (not a discretionary trade); F3–F4—describe the RSU vesting schedules underlying the conversions.
• Filing date: Form 4 filed 2026-05-26; timing appears consistent with standard Form 4 reporting deadlines.

Context

• The filing reflects RSU settlement and a routine sell-to-cover for taxes rather than a discretionary sale for investment reasons. For retail investors, such tax-related sales are common following vesting and generally do not by themselves signal a change in insider sentiment.